BioSpace News Archive

A first-of-its-kind study to help treat Urinary Tract Infections (UTIs) is underway through a research partnership with one of the world’s leading medical experts in treating UTIs and a company that uses advanced DNA technology to identify microbes that cause infection so that doctors can target precise medical treatment. Dr. J. Curtis Nickel , Research Chair in Urologic Pain and Inflammation at Kingston General Hosp

LifeLabs is pleased to share that it has been selected as the medical laboratory partner for the NHL’s Return to Play Plan as part of LifeLabs’ WorkClear program, an evidence-based approach to help companies bring employees safely back to work.

- One oral presentation and eight posters, highlighting Eisai’s investigational novel therapies being studied to treat Alzheimer’s disease (AD) and its clinical symptoms - New biomarker research approaches will be shared as part of symposium featuring prominent experts in the field

Glycosyn LLC, a pioneer in in the field of Human Milk Oligosaccharides (HMOs), which are prebiotics known to support a healthy gut microbiome, and which were previously found only in breast milk, announced today that the exclusion order issued by the

-- The combination of SmartPharm’s Gene Mab™ gene-encoded in vivo expression system and Sorrento’s SARS-CoV-2 neutralizing antibodies may potentially provide longer-acting, single injection protection against COVID-19. -- The combination of Sorrento’s proprietary fully human G-MAB™ Antibody Library and SmartPharm’s Gene-Encoded Therapeutics (GET) Platform is expected to provide a vast product pipeline of novel, long-acting therapeutic proteins for treating a broad range of diseases, in

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Friday, July 31, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1677593. Participants are encouraged to connect 15 minutes in advance of

— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med —

AnHeart Therapeutics, Co., Ltd. announced that it plans to make a corporate presentation at the LifeSci Partners Summer Symposium virtual conference.

The Phase 3b BE RADIANT study met its primary endpoint and all ranked secondary endpoints

- If Approved, ARIKAYCE Will Be First and Only Therapy in the European Union for This Difficult-to-Treat Condition - - Decision from European Commission Expected Second Half of 2020 -